Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Avenge Bio Closes $45 Million Series A Financing

Brendan McLaughlin - Process Development & Manufacturing Scientist - Avenge Bio

Avenge Bio on LinkedIn: Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian…

Avenge Bio secures FDA designation for mesothelioma therapy

Avenge Bio completes first dose cohort in AVB-001 Phase I/II trial

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Bio Tech Nutra Avenger - Stack3d Database

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Zeke Johnston - Senior Director, External Manufacturing & Supply Chain at Avenge Bio

Reality of Rare Diseases: A Unique Perspective About Rare Diseases

Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte™ Immunotherapy Platform

Enrollment information for DRUG FACTORY Implants in Ovarian Cancer Trial is now up on the Clinical Trials website! 👏 Check here:, By Ovarcome